Business Combinations and Other Strategic Investments (Details) (USD $)	3 Months Ended								12 Months Ended						12 Months Ended		12 Months Ended		0 Months Ended			12 Months Ended		0 Months Ended		0 Months Ended	12 Months Ended			12 Months Ended	0 Months Ended	12 Months Ended				1 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Aciex Therapeutics Inc. [Member]	Sep. 30, 2011 Aciex Therapeutics Inc. [Member]	Aug. 01, 2011 Aciex Therapeutics Inc. [Member]	Dec. 31, 2013 Kilitch Drugs (India) Limited [Member]	Feb. 28, 2012 Kilitch Drugs (India) Limited [Member]	Dec. 31, 2013 Kilitch Drugs (India) Limited [Member] Minimum [Member]	Dec. 31, 2013 Kilitch Drugs (India) Limited [Member] Maximum [Member]	Feb. 28, 2012 Kilitch Drugs (India) Limited [Member] Initial Fair Valuation [Member]	Feb. 28, 2012 Kilitch Drugs (India) Limited [Member] Change in Estimate [Member]	Feb. 28, 2012 Kilitch Drugs (India) Limited [Member] Adjusted Fair Valuation [Member]	Dec. 31, 2013 H. Lundbeck AS [Member]	Dec. 22, 2011 H. Lundbeck AS [Member] Product	Dec. 22, 2011 H. Lundbeck AS [Member] Initial Fair Valuation [Member]	Dec. 22, 2011 H. Lundbeck AS [Member] Change in Estimate [Member]	Dec. 22, 2011 H. Lundbeck AS [Member] Adjusted Fair Valuation [Member]	Dec. 31, 2013 Hi-Tech Pharmacal Co. Inc [Member]	Aug. 26, 2013 Hi-Tech Pharmacal Co. Inc [Member]	Jan. 31, 2014 Hi-Tech Pharmacal Co. Inc [Member] Subsequent Event [Member]	Dec. 31, 2013 Hi-Tech Pharmacal Co. Inc [Member] JPM Term Loan [Member]	May 03, 2011 Advanced Vision Research, Inc. [Member]	Dec. 31, 2013 Advanced Vision Research, Inc. [Member]	Dec. 31, 2011 Advanced Vision Research, Inc. [Member]	Dec. 31, 2013 Advanced Vision Research, Inc. [Member] Trademarks and Technology [Member]	Dec. 31, 2013 Advanced Vision Research, Inc. [Member] Customer Relationships [Member]	Dec. 31, 2013 Merck Products [Member]	Dec. 31, 2013 Merck Products [Member]	Nov. 15, 2013 Merck Products [Member] Product	Dec. 31, 2013 Merck Products [Member] Aza Site [Member]	Dec. 31, 2013 Merck Products [Member] Cosopt [Member]	Dec. 31, 2013 Merck Products [Member] Cosopt PF [Member]
Business Acquisition [Line Items]
Business Acquisition Effective date of acquisition															Feb. 28, 2012																	May 03, 2011
Business Acquisition Agreement date of acquisition															Oct. 05, 2011							Dec. 22, 2011					Aug. 26, 2013
Total cash paid at closing																$ 60,100,000
Business acquisition price per share (in dollars per share)																												$ 43.50
Merger Agreement termination fee 1,																											41,600,000
Merger Agreement termination fee 2																											48,000,000
Merger Agreement termination fee 3																											20,800,000
Merger Agreement termination fee 4																											32,000,000
Expected term loan amount to fund acquisition																														600,000,000
Maturity period of term loan																														7 years
Deferred financing fees									3,032,000	0	5,098,000																			3,400,000
Business Acquisition, par value of Hi-Tech common stock (in dollars per share)																												$ 0.01
Base consideration paid																51,200,000
Reimbursement for capital expenditure																4,000,000
Contingent consideration payable	15,000,000								15,000,000														11,600,000								181,000
Consideration [Abstract]
Cash paid													2,000,000	8,000,000					55,224,000		55,224,000		45,000,000	49,559,000		49,559,000					26,011,000					52,800,000	52,800,000
Less working capital shortfall due back from sellers																			(890,000)	(138,000)	(1,028,000)
Additional consideration paid																															723,000
Present value of contingent consideration																								11,300,000	300,000	11,600,000
Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents																													86,000,000
Total consideration																			54,334,000	(138,000)	54,196,000			60,859,000	300,000	61,159,000		640,000,000			26,734,000
Acquisition-related costs [Abstract]
Stamp duties paid for transfer of land and buildings																			1,583,000		1,583,000
Acquisition-related compensation expense																			6,741,000	511,000	7,252,000
Due diligence, legal, travel and other acquisition-related costs																			557,000	119,000	676,000
Acquisition-related costs									2,912,000	9,155,000	743,000								8,881,000	630,000	9,511,000			50,000		50,000	1,600,000				246,000
Recognized amounts of identifiable assets acquired and liabilities assumed [Abstract]
Product rights total																																				55,700,000	55,700,000		13,800,000	21,600,000	20,300,000
Prepaid expenses																															730,000					48,000	48,000
Deferred tax assets, net																																				759,000	759,000
Total fair value of acquired assets																																				56,507,000	56,507,000
Consideration paid													2,000,000	8,000,000					55,224,000		55,224,000		45,000,000	49,559,000		49,559,000					26,011,000					52,800,000	52,800,000
Gain from bargain purchase									3,707,000	0	0																										3,707,000
Accounts receivable																			2,130,000		2,130,000										611,000
Product licensing rights	2,700,000				800,000				2,700,000	800,000	5,700,000													59,525,000	300,000	59,825,000
Inventory											300,000								1,799,000		1,799,000			3,825,000		3,825,000					3,407,000
Land																			3,714,000	(1,131,000)	2,583,000
Prepaid expenses and other current assets																															730,000					48,000	48,000
Buildings, plant and equipment																			8,474,000		8,474,000										250,000
Construction in progress																			14,231,000		14,231,000
Goodwill, deductible																			21,609,000	1,004,000	22,613,000										11,863,000
Other intangible assets, deductible																			5,806,000	102,000	5,908,000
Trademarks and technology																															9,500,000
Customer relationships																															3,900,000
Other assets																			38,000		38,000
Assumed liabilities																			(2,099,000)	(779,000)	(2,878,000)
Deferred tax liabilities																			(1,368,000)	666,000	(702,000)
Fixed assets																								50,000		50,000
Assumed liability - unfavorable contract																								(2,541,000)		(2,541,000)
Estimated additional consideration due	(15,000,000)								(15,000,000)														(11,600,000)								(181,000)
Accounts payable & other assumed liabilities																															(3,346,000)
Business combination, recognized amounts of identifiable assets acquired and liabilities assumed, net																			54,334,000	(138,000)	54,196,000			60,859,000	300,000	61,159,000					26,734,000
Acquired finite-lived intangible assets useful life																	4 years	5 years				15 years										15 years		30 years	15 years
Revenue	84,953,000	81,892,000	77,012,000	73,854,000	71,520,000	69,634,000	63,287,000	51,717,000	317,711,000	256,158,000	136,920,000																						600,000			1,600,000
Income before taxes									82,895,000	57,500,000	41,306,000																									1,400,000
Business acquisition estimated purchase price																							63,400,000
Business acquisition cost of acquired entity upfront cash paid																							45,000,000
Cash payable for acquired inventory																							4,600,000
First consecutive performance period subsequent to closing																							3 years
Second consecutive performance period subsequent to closing																							3 years
Assumed discount rate (in hundredths)									9.00%													9.00%
Period prior to expiration of inventory for selling, minimum																						6 months
Royalty as percentage of gross profit margin on sales of product (in hundredths)																						55.00%
Period for royalty payment on sale of product																						6 years
Incremental income tax expense of acquiree reimbursed																															700,000
Net cash balance in AVR's bank accounts																															700,000
Gross accounts receivable																															2,700,000
Product returns									5,000,000	3,800,000	2,700,000																				1,800,000
Allowance for doubtful accounts																															200,000
Cash discounts																															$ 100,000
Number Of Products To Acquire U.S. Rights Under Asset Sale And Purchase Agreement																																						3
Number of products to acquire NDA rights under Asset Sale and Purchase Agreement																							3
Ownership interest amount is below (in hundredths)												20.00%